BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2017

View Archived Issues

Skinvisible and Quoin Pharmaceuticals enter non-binding term sheet for proposed merger

Read More

HEALOS phase III study of AM-111 does not meet the primary efficacy endpoint

Read More

Positive topline data reported from Abide Therapeutics' phase Ib study of ABX-1431

Read More

Aptevo Therapeutics to conduct phase II study of otlertuzumab

Read More

Preclinical antidepressant effects seen with sestrin-2 modulator NV-5138

Read More

C-458 shows promising results for Alzheimer's disease treatment

Read More

G1 Therapeutics enters clinical trial collaboration with AstraZeneca

Read More

Viking Therapeutics phase II study of VK-5211 meets primary endpoint

Read More

PhaseBio Pharmaceuticals obtains license to ticagrelor reversal agent

Read More

Synpromics and UCL enter Parkinson's disease gene therapy collaboration

Read More

Gilead and X-Chem form drug discovery collaboration

Read More

Phase III JAVELIN Gastric 300 trial of avelumab does not meet primary endpoint

Read More

FDA grants priority review to mogamulizumab BLA for CTCL

Read More

Takeda Pharmaceutical commences phase I study of Zika vaccine candidate TAK-426

Read More

GSK seeks U.S. approval for tafenoquine for prevention of relapse of P. vivax malaria

Read More

Hepatera and MYR report interim results from phase IIb study of Myrcludex B

Read More

Charles River and Enyo collaborate to identify mode of action of EYP002 series

Read More

Phase I data support inclusion of adolescents in Ovid's phase II trial of OV-101

Read More

Researchers present new DT-induced PAH animal model

Read More

Phase I studies reveal signs of antiparkinsonian efficacy of PF-06649751

Read More

Abide Therapeutics describes novel monoglyceride lipase/monoacylglycerol lipase ABHD6 inhibitors

Read More

New anti-tenascin-C antibodies synthesized at Roche

Read More

A*STAR presents novel anti-CTLA-4 antibodies

Read More

Novel Staphylococcus epidermidis autoinducing peptide analogues discovered at WARF

Read More

TNB-383B, a novel bispecific antibody candidate with efficacy in multiple myeloma models

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing